|
|
 |
|
Viewing report
|
|
|
|
H1N1 (Swine Influenza) - Pipeline Assessment and Market Forecasts to 2017
GlobalData, March 2011, Pages: 82
H1N1 (Swine Influenza) - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “H1N1 (Swine Influenza) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global H1N1 (Swine Influenza) Therapeutics market. The report identifies the key trends shaping and driving the global H1N1 (Swine Influenza) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global H1N1 (Swine Influenza) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated that the H1N1 (Swine Influenza) therapeutics market to be worth $6.77 billion in 2010. GlobalData expects the H1N1 (Swine Influenza) therapeutics market to decline at a compound annual growth rate (CAGR) of 4% from $6.77 billion in 2010 to $5 billion approximately in 2017. The negative growth is primarily due to the fact that the pandemic has now moved into the post pandemic stage. Moreover the expiration of major drug patents, namely Tamiflu (2016) and Relenza (2013) are also going to put a negative impact on the growth of this market.
Scope
The report provides information on the key drivers and challenges of the H1N1 (Swine Influenza) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) H1N1 (Swine Influenza) Therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as inactivated cell vaccines, Antigenic vaccines, Anti-M2e human antibody, hemagglutinin binder, human rhinovirus inhibitor, T-cell modulator, neuraminidase inhibitors and aganocide compound.
- Analysis of the current and future competition in the seven key countries H1N1 (Swine Influenza) Therapeutics market. Key market players covered are GlaxoSmithKline, Sanofi-Aventis, Novartis, CSL Ltd and Astra Zeneca.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the H1N1 (Swine Influenza) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in H1N1 (Swine Influenza) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global H1N1 (Swine Influenza) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global H1N1 (Swine Influenza) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global H1N1 (Swine Influenza) Therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
